Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Rang in Aktien #16421
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Aktienkurs
$4.64
Zuletzt synchronisiert: 2022-09-12
Marktkapitalisierung
$293.43M
Veränderung (1 Tag)
0.87%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Adagio Therapeutics, Inc. (ADGI)

Kategorie

Aktien-Split-Historie für Adagio Therapeutics, Inc. (ADGI)
Die Aktie Adagio Therapeutics, Inc. (Symbol: ADGI) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Sep 02, 2026 statt.
Eine ADGI-Aktie, die vor dem Sep 02, 2026 gekauft wurde, entspricht heute 0 ADGI-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH